カテゴリ： GlobalData, イギリス, 企業調査

Theravance Biopharma Inc (TBPH)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Theravance Biopharma Inc (TBPH) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C9855
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：60
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：イギリス
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Theravance Biopharma Inc (Theravance Biopharma) is a diversified biopharmaceutical company. Its flagship product, Vibativ (telavancin) is a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to Staphylococcus aureus and other Gram-positive bacteria, including methicillin-resistant (MRSA) strains. Its major pipeline programs targeted towards the treatment of chronic obstructive pulmonary disease (COPD); asthma; neurogenic orthostatic hypotension (nOH); opioid-induced constipation (OIC); hepatitis C virus; gastrointestinal motility disorders; ulcerative colitis; heart failure; chronic kidney disease (CKD); Crohn’s disease; gastroparesis; concurrent bacteremia; rheumatoid arthritis; and myelofibrosis and blood pressure. The company has subsidiaries in the US, Ireland and the UK. Theravance is headquartered in George Town, Cayman Islands, the UK.

Theravance Biopharma Inc (TBPH) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Licensing Agreements 13
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Equity Offering 16
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Debt Offering 23
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Asset Transactions 25
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc – Key Competitors 26
Theravance Biopharma Inc – Key Employees 27
Theravance Biopharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update 29
Aug 01, 2018: Theravance Biopharma reports second quarter 2018 financial results and provides business update 31
May 08, 2018: Theravance Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 27, 2018: Theravance Biopharma Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update 37
Aug 08, 2017: Theravance Biopharma Reports Second Quarter 2017 Financial Results and Provides Business Update 39
May 09, 2017: Theravance Biopharma Reports First Quarter 2017 Financial Results and Provides Business Update 41
Feb 27, 2017: Theravance Biopharma Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 43
Corporate Communications 45
Jul 31, 2017: Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy 45
Product News 46
05/17/2017: Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 46
01/29/2018: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 47
01/23/2017: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress 48
01/17/2017: Theravance Biopharma to Present New Data from Ongoing TOUR Observational Patient Registry at SCCM Critical Care Congress 50
Product Approvals 51
Nov 13, 2017: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 51
Clinical Trials 52
Nov 01, 2017: Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting 52
Oct 24, 2017: Theravance Biopharma to Present New Data on Revefenacin (TD-4208) at 2017 CHEST Annual Meeting 54
Jul 19, 2017: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 55
May 23, 2017: Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 56
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 58
Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc, Key Competitors 26
Theravance Biopharma Inc, Key Employees 27
Theravance Biopharma Inc, Subsidiaries 28

List of Figures
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Theravance Biopharma Inc (TBPH)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Qatar Islamic Bank：企業の戦略・SWOT・財務分析
    Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report Summary Qatar Islamic Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Dunavant Enterprises, Inc.
    Dunavant Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report Summary Dunavant Enterprises, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • SEAS-NVE Holding AS：企業の戦略的SWOT分析
    SEAS-NVE Holding AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Kracie Holdings, Ltd.：企業の戦略・SWOT・財務情報
    Kracie Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Kracie Holdings, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Fairfield Energy Ltd：石油・ガス：M&Aディール及び事業提携情報
    Summary Fairfield Energy Ltd (Fairfield Energy), a subsidiary of Decom Energy Ltd is an oil and gas company that offers oil and gas decommissioning services. The company acquires and develops hydrocarbon properties. It acquires and operates marginal fields in the UK continental shelf. Fairfield Ener …
  • Aspen Pharmacare Holdings Ltd (APN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Aspen Pharmacare Holdings Ltd (Aspen) is a specialty and generic pharmaceuticals company that provides pharmaceutical drugs for a range of acute and chronic conditions. The company focuses on thrombosis, anesthetics and high potency and cytotoxics therapeutic categories. It also manufactures …
  • Lutron Electronics Co Inc：企業の戦略的SWOT分析
    Lutron Electronics Co Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • G-III Apparel Group, Ltd.：企業の戦略・SWOT・財務情報
    G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report Summary G-III Apparel Group, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Hamburg Commercial Bank：企業の戦略・SWOT・財務分析
    Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report Summary Hamburg Commercial Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • ITC Holdings Corp.：発電所・企業SWOT分析
    ITC Holdings Corp. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Nordstrom Inc (JWN)：企業の財務・戦略的SWOT分析
    Nordstrom Inc (JWN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • ADESA Inc：企業の戦略的SWOT分析
    ADESA Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis – 2017
    JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis - 2017 Summary JX Nippon Oil & Gas Exploration Corp Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that o …
  • Comtek Advanced Structures Ltd.：企業の戦略・SWOT・財務情報
    Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report Summary Comtek Advanced Structures Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • MedImmune LLC：企業の戦略的SWOT分析
    MedImmune LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Siemens Gamesa Renewable Energy SA (SGRE)：企業の財務・戦略的SWOT分析
    Siemens Gamesa Renewable Energy SA (SGRE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • PGE Polska Grupa Energetyczna SA (PGE)-エネルギー分野：企業M&A・提携分析
    Summary PGE Polska Grupa Energetyczna S.A. (PGE) is a state owned energy utility, which produces and supplies electricity in Poland. It carries out lignite mining activities, electricity generation from fossil fuels (lignite, hard coal and natural gas) and renewable energy sources (hydro, wind and b …
  • Wal-Mart Stores Inc：戦略・SWOT・企業財務分析
    Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report Summary Wal-Mart Stores Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Canacol Energy Ltd (CNE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Canacol Energy Ltd (Canacol Energy) is an oil and gas company that explores and produces conventional and unconventional oil fields. The company operates oil and gas reserves in Caguan-Putumayo basin, Lower Magdalena basin, Llanos basin, Magdalena basin in Colombia; and Oriente basin in Ecua …
  • Newcastle University-製薬・医療分野：企業M&A・提携分析
    Summary Newcastle University (NU) is an educational university that offers teaching and research services. The university provides teaching and study services including postgraduate study, undergraduate study, and campus services. It offers teaching services in areas of accounting and finance; agri- …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆